A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

Launched by BOEHRINGER INGELHEIM · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study how a medication called BI 1584862 is processed in the blood of adults who have liver problems, as well as those who do not have any liver issues. The researchers want to understand how different levels of liver health—mild, moderate, and severe—affect how the body handles this medication. The study is open to men and women aged 18 to 80 with a body mass index (BMI) between 18 and 42. Participants with liver problems will be monitored closely, and they can continue their usual liver treatments during the study.

If you choose to participate, you would be involved for about five weeks, with three visits to the study center, including an overnight stay for four nights. During these visits, doctors will check your health and collect blood samples to monitor any side effects and how well the medication is working. It’s important to note that there are specific criteria for participating, such as being in good overall health apart from liver issues, and certain health conditions may disqualify you from joining. Always consult with your doctor to see if this trial might be a good fit for you.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Inclusion criteria applicable to all participants
• • Male or female participants
• • Age of 18 to 80 years (inclusive)
• • Body mass index (BMI) of 18.0 to 42 kg/m2 (inclusive)
• • Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
• • Men participants must be willing and able to use contraception (condom, abstinence) from time point of administration of trial medication until 3 days after drug administration to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. Female partners do not need to use contraception
• * Women of childbearing potential are allowed to participate provided they use a highly effective contraception from at least 30 days before the administration of trial medication until 30 days after administration of trial medication. The following methods of contraception are considered adequate for female participants of childbearing potential:
• • Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants), plus condom
• • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
• • Sexually abstinent (true abstinence, in line with the preferred and usual lifestyle of the subject)
• • A vasectomised sexual partner who received medical assessment of the surgical success (documented absence of sperm) and provided that partner is the sole sexual partner of the trial participant.
• • Female participants are not considered to be of childbearing potential if they are either surgically sterilised (including hysterectomy) or postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of Follicle stimulating hormone (FSH) above 40 U/L and oestradiol below 30 ng/L is confirmatory).
• • Further inclusion criteria apply.
• Exclusion criteria:
• • Exclusion criteria for all participants
• • Any medical condition or finding in the medical examination (including blood pressure (BP), pulse rate (PR) or Electrocardiogram (ECG)) assessed as clinically relevant by the investigator (apart from any hepatic impairment and associated underlying diseases)
• • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance (apart from values due to underlying disease)
• • Any evidence of a concomitant disease assessed as clinically relevant by the investigator (apart from underlying disease)
• • For diabetics only: uncontrolled diabetes mellitus with an Hemoglobin A1c (HbA1c) \> 9
• • Severe gastrointestinal, renal (Estimated glomerular filtration rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \<40 ml/min/1.73 m2 for the hepatic impaired patients and eGFR CKD-EPI \<90 ml/min/1.73 m2 for matched controls), respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the Investigator.
• • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
• • History of relevant orthostatic hypotension, repetitive fainting spells, or repetitive blackouts
• • Relevant chronic or acute infections Further exclusion criteria apply.